The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Cancer Policy

NIH suspends new embryonic stem cell line submissions

CMS to enter negotiations with drugmakers over the price of four cancer medications

Tens of thousands of healthcare workers strike across the country

FDA delays drug reviews in new voucher program amid safety, efficacy concerns

NIH ends fetal tissue research—again

ACA Marketplace enrollments down by 1.4 million, early data shows

Clinical Roundup

Trodelvy + Keytruda show potential as new standard of care in first-line PD-L1+ metastatic TNBC, phase III trial finds

Elenagen DNA-based therapy achieves significant reduction in mortality and increase in OS in PROC

Extracellular vesicles drug delivery mechanism could aid breast cancer treatment, UF study finds

Researchers find cell markers to track TNBC, Baylor College of Medicine study finds

Sylvester-led study focuses on rate of failure in head and neck cancer trials

Researchers develop tool that can identify high- and low-risk metastatic prostate cancer patients earlier

In The Clinic
News Analysis

ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook

Health Equity
Trials & Tribulations
Trials & Tribulations

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account